Abstract:BACKGROUND: Mechanically ventilated patients often need bronchodilators administered via a metered-dose inhaler (MDI).similar between the shared canister and single-patient canister groups. We did not observe clinically important differences for ventilator-associated events between study groups in our logistic regression analysis (P ؍ .07). There was a savings of $217/subject in the shared canister group due to the use of 299 fewer MDIs. CONCLUSIONS: Our study found that shared canister MDI therapy compared … Show more
“…Furthermore, a prospective trial demonstrated that a shared canister protocol for the delivery of MDIs was associated with a $40,000 cost savings without any differences in ventilator days, ventilator-associated pneumonias, or hospital mortality. 55 Although ventilator-associated events were noted to be more prevalent in the shared canister arm compared with the standard care arm, these findings are unclear because ventilator-associated events are more often used for surveillance at the population level rather than at the bedside. Nonetheless, although this approach may reduce waste, additional safety data on this approach as well as established infection control practices are needed prior to widespread implementation.…”
Section: Albuterol/ipratropiummentioning
confidence: 99%
“…Nonetheless, although this approach may reduce waste, additional safety data on this approach as well as established infection control practices are needed prior to widespread implementation. 55…”
Pharmaceutical costs for patients in the intensive care unit (ICU) constitute a large portion of hospital drug budgets. Unfortunately, prices for medications commonly used in the ICU are on the rise for a variety of reasons. In particular, the U.S. Food and Drug Administration's Unapproved Drugs Initiative, generic manufacturers cornering the marketplace, drug shortages, and regulatory device changes are major drivers of pharmaceutical price escalation affecting costs in the ICU. Furthermore, traditional high acquisition cost items still pose challenges to controlling costs. To offer strategies to mitigate the rising costs of pharmaceuticals in the ICU setting, we searched the PubMed/Medline and International Pharmaceutical Abstracts databases and other related sources to identify published cost-saving protocols concerning specific medications that are affected by rising prices or have traditional high acquisition costs. In the absence of specific protocols, we offer possible cost-saving initiatives based on published literature regarding specific agents or based on our own diverse set of experiences. Finally, we review suggested clinical and operational activities at an institutional level to address these rising drug costs in the ICU setting.
“…Furthermore, a prospective trial demonstrated that a shared canister protocol for the delivery of MDIs was associated with a $40,000 cost savings without any differences in ventilator days, ventilator-associated pneumonias, or hospital mortality. 55 Although ventilator-associated events were noted to be more prevalent in the shared canister arm compared with the standard care arm, these findings are unclear because ventilator-associated events are more often used for surveillance at the population level rather than at the bedside. Nonetheless, although this approach may reduce waste, additional safety data on this approach as well as established infection control practices are needed prior to widespread implementation.…”
Section: Albuterol/ipratropiummentioning
confidence: 99%
“…Nonetheless, although this approach may reduce waste, additional safety data on this approach as well as established infection control practices are needed prior to widespread implementation. 55…”
Pharmaceutical costs for patients in the intensive care unit (ICU) constitute a large portion of hospital drug budgets. Unfortunately, prices for medications commonly used in the ICU are on the rise for a variety of reasons. In particular, the U.S. Food and Drug Administration's Unapproved Drugs Initiative, generic manufacturers cornering the marketplace, drug shortages, and regulatory device changes are major drivers of pharmaceutical price escalation affecting costs in the ICU. Furthermore, traditional high acquisition cost items still pose challenges to controlling costs. To offer strategies to mitigate the rising costs of pharmaceuticals in the ICU setting, we searched the PubMed/Medline and International Pharmaceutical Abstracts databases and other related sources to identify published cost-saving protocols concerning specific medications that are affected by rising prices or have traditional high acquisition costs. In the absence of specific protocols, we offer possible cost-saving initiatives based on published literature regarding specific agents or based on our own diverse set of experiences. Finally, we review suggested clinical and operational activities at an institutional level to address these rising drug costs in the ICU setting.
“…[ 209 ] In contrast, a recent study revealed that common canister protocol resulted in significant cost savings with similar rates of ventilator-associated pneumonia, mortality, as well as hospital length of stay, compared to single-patient pMDI. [ 210 ] Accordingly, each hospital should evaluate the risk–benefit ratio before following a common canister protocol. [ 25 ]…”
Section: Aerosol Therapy At Home: Education and Cleaningmentioning
The Saudi Pediatric Pulmonology Association (SPPA) is a subsidiary of the Saudi Thoracic Society (STS), which consists of a group of Saudi experts with well-respected academic and clinical backgrounds in the fields of asthma and other respiratory diseases. The SPPA Expert Panel realized the need to draw up a clear, simple to understand, and easy to use guidance regarding the application of different aerosol therapies in respiratory diseases in children, due to the high prevalence and high economic burden of these diseases in Saudi Arabia. This statement was developed based on the available literature, new evidence, and experts' practice to come up with such consensuses about the usage of different aerosol therapies for the management of respiratory diseases in children (asthma and nonasthma) in different patient settings, including outpatient, emergency room, intensive care unit, and inpatient settings. For this purpose, SPPA has initiated and formed a national committee which consists of experts from concerned specialties (pediatric pulmonology, pediatric emergency, clinical pharmacology, pediatric respiratory therapy, as well as pediatric and neonatal intensive care). These committee members are from different healthcare sectors in Saudi Arabia (Ministry of Health, Ministry of Defence, Ministry of Education, and private healthcare sector). In addition to that, this committee is representing different regions in Saudi Arabia (Eastern, Central, and Western region). The subject was divided into several topics which were then assigned to at least two experts. The authors searched the literature according to their own strategies without central literature review. To achieve consensus, draft reports and recommendations were reviewed and voted on by the whole panel.
“…14 Although pMDI use remains common during mechanical ventilation, there is ongoing contention regarding the use of shared (common) canister protocol versus single canister therapy. Gowen et al 21 found that common canister protocol does yield cost savings but may result in more ventilator-associated events. A study by Ari et al 14 suggested that the use of a vibrating mesh nebulizer during mechanical ventilation was superior to the use of traditional jet nebulizer with a 2-4-fold greater drug delivery, but there may be significant variance among certain models of vibrating mesh nebulizers affecting the overall consistency of dosing.…”
Section: See the Original Study On Page 391mentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.